Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Solid Tumor, Adult 1Neoplasm Metastasis 1Colorectal Neoplasms 1

Interventions

Bevacizumab 187Fluorouracil 150Leucovorin 135Cetuximab 127Irinotecan 114Oxaliplatin 108pembrolizumab 96Capecitabine 82IFL protocol 53Panitumumab 43Nivolumab 43regorafenib 42Folfox protocol 39Gemcitabine 30trifluridine tipiracil drug combination 27Cisplatin 24Carboplatin 24atezolizumab 23Pemetrexed 20Paclitaxel 20Drug Therapy 20130-nm albumin-bound paclitaxel 17Trastuzumab 14encorafenib 13Trifluridine 13Ipilimumab 13HMPL-013 13tislelizumab 12spartalizumab 11Docetaxel 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Colorectal Neoplasms × EBI-005 × Clear all
NCT06634875 2026-03-31

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

Buzzard Pharmaceuticals

Phase 2 Recruiting
20 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡